ESMO Virtual Congress 2020: Novel, Oral Tubulin Inhibitor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Blocking Agent: Phase Ib/II Study of VERU-111

(UroToday.com) While multiple new therapies have been shown to prolong overall survival in metastatic castration-resistant prostate cancer (mCRPC), resistance inevitably develops. In this presentation, Dr. Markowski presents results from a phase 1b/2 study of a novel tubulin inhibitor called VERU-111 in men with mCRPC who failed prior therapy with an anti-androgen.